3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
10
Neoplasms
4
Neoplasm Metastasis
2
Leiomyosarcoma
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
15
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Magnetic Resonance Spectroscopy
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
X-Rays
3
Vincristine
3
Radiation
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
cixutumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liposarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts